BioPharma Innovation a Strength of Holland’s Life Sciences Sector
Dutch biopharma experts to participate in BIO-Europe Spring 2018, in Amsterdam
Multinational biopharma companies know that the Netherlands offers high-quality infrastructure for pharmaceutical data and analysis thanks to its well-documented population. This strength will be on the world stage during BIO-Europe Spring 2018, in Amsterdam March 12-14.
“In the Netherlands, collaboration is in our genes,” Annemiek Verkamman, Managing Director of HollandBIO recently wrote. “In a joint effort, the Dutch are pioneering solutions that combine health, affordability and innovation: organoid and organ-on-a-chip technology to realise better disease models, FAIR data technology unleashing the power of our research infrastructure, and public-private partnerships such as Oncode Institute and RegMed XB that bundle scientific excellence and best practices in valorisation, to name a few.”
As a national partner of this year’s conference, Health~Holland will showcase the country’s biopharmaceutical expertise through several events. A full list of Dutch events at BIO-Europe Spring can be found here. Attendees can also meet up with the Invest in Holland team at booth #72, where you can also network and learn from leading Dutch biotech entrepreneurs and scientists.
Dutch Ecosystem Fuels BioPharma Innovation
BIO-Europe Spring comes on the heels of the General Affairs Council of the European Union announcing in late 2017 that the European Medicines Agency (EMA) will relocate to Amsterdam when it leaves London in 2019. EMA is the body responsible for assessing the efficacy, quality, and safety of new medicines, for human and animal health, before they are approved for the European market. In addition, the organisation supervises the safety of authorised medicines and promotes research into and the development of new medicines.
The Netherlands Medicines Evaluation Board (MEB) is one of the top European regulators for central and pharmacovigilance procedures and a major contributor of expertise to the European network of pharmaceutical authorities coordinated by EMA. Amsterdam becoming the new home for EMA in Spring 2019, will strengthen the Dutch ecosystem for all human and veterinary medicines. It will also boost the Netherlands’ attractiveness to other companies and institutions in life sciences and health.
Multinationals and innovative biotech companies like Janssen, Merck (MSD), Amgen, Sanofi, Genmab, Synthon, AstraZeneca, Kite Pharma, Aduro Biotech, Galapagos, AbbVie, Kiadis, Pharming, Merus and PRA Health Sciences are already in the Netherlands. State-of-the-art research institutes also support the sector ecosystem in Holland. In addition, the life sciences & health network in the Netherlands includes 12 research universities and eight university medical centers, all working together to advance global biopharmaceutical innovation and Dutch leadership.
Source: NFIA and Health~Holland